The InSciTe Biomedical Matrix welcomes VACIS as new partnernovember 22, 2017
VACIS, a biomedical startup company, is partnering with the (Bio)medical Matrix of InSciTe at Brightlands Chemelot Campus. By choosing the right elements provided by the Matrix, VACIS will accelerate their process towards clinical trials and market launch.
VACIS was founded in 2016 and is a spin-off from technology developed by Maastricht University and Leiden Universitair Medisch Centrum. The company develops in-situ tissue engineered blood vessels, providing novel therapeutic options for vascular surgery. VACIS provides patients autologous graft vessels. VACIS’ technology uses a synthetic rod device, which is inserted under the skin and induces the formation of a new, fully functional blood vessel. After 28 days of implantation, the rod-like device is removed leaving in place an in-situ formed vessel of fibro collagenous tissue which further matures into a functional blood vessel following connection into the blood circulation.
By partnering with InSciTe, VACIS plans to enter the clinical phase in 2018 and market launch in 2019/20.
Go to VACIS for more information.